BioCardia (STU:6JU0) Accounts Payable: €0.47 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6JU0 BioCardia Inc STU:6JU0
23 GF Score
Price €0.27
! 1 Warning Sign
View Full Analysis

What is BioCardia Accounts Payable?

BioCardia STU:6JU0 23 Accounts Payable is €0.47 Mil as of Jun. 2026. GuruFocus rates STU:6JU0 with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

BioCardia's Accounts Payable for the quarter that ended in Jun. 2026 was €0.47 Mil.

BioCardia's quarterly Accounts Payable increased from Dec. 2025 (€0.55 Mil) to Mar. 2026 (€0.71 Mil) but then declined from Mar. 2026 (€0.71 Mil) to Jun. 2026 (€0.47 Mil).

BioCardia's annual Accounts Payable declined from Dec. 2023 (€0.82 Mil) to Dec. 2024 (€0.37 Mil) but then increased from Dec. 2024 (€0.37 Mil) to Dec. 2025 (€0.55 Mil).

BioCardia Accounts Payable Historical Data

* Premium members only.

The historical data trend for BioCardia's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioCardia Accounts Payable Chart

BioCardia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.65 0.82 0.37 0.55

BioCardia Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.07 0.92 0.55 0.71 0.47
STU:6JU0
23GF Score
BioCardia Inc STU:6JU0
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioCardia Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.47 Mil mean?
BioCardia (STU:6JU0) has a Accounts Payable of €0.47 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BioCardia and its competitors.
Is BioCardia's Accounts Payable too high?
BioCardia's current Accounts Payable is €0.47 Mil. Overall, BioCardia has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's Accounts Payable compare to ZIVO and CYCN?
BioCardia's Accounts Payable of €0.47 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BioCardia and its competitors. BioCardia's current Accounts Payable is €0.47 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (STU:6JU0) has a current Accounts Payable of €0.47 Mil. The current Accounts Payable is €0.47 Mil. BioCardia's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BioCardia (STU:6JU0), the current Accounts Payable is €0.47 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioCardia Business Description

Other Exchanges BCDA:USA
Address 320 Soquel Way, Sunnyvale, CA, USA, 94085
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
23GF Score

Get the complete analysis for STU:6JU0

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price